Liquidia Technologies Inc. (LQDA)’s Financial Results Comparing With Aravive Inc. (NASDAQ:ARAV)

Liquidia Technologies Inc. (NASDAQ:LQDA) and Aravive Inc. (NASDAQ:ARAV) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Liquidia Technologies Inc. 1.78M 90.44 39.39M -3.40 0.00
Aravive Inc. 3.07M 21.30 72.06M -8.98 0.00

In table 1 we can see Liquidia Technologies Inc. and Aravive Inc.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 provides us the return on equity, return on assets and net margins of both businesses.

Net Margins Return on Equity Return on Assets
Liquidia Technologies Inc. -2,212.92% 0% 0%
Aravive Inc. -2,347.23% -116.4% -97.4%


Liquidia Technologies Inc. has a Current Ratio of 5.6 and a Quick Ratio of 5.6. Competitively, Aravive Inc.’s Current Ratio is 7.8 and has 7.8 Quick Ratio. Aravive Inc.’s better ability to pay short and long-term obligations than Liquidia Technologies Inc.

Insider and Institutional Ownership

Roughly 44.4% of Liquidia Technologies Inc. shares are owned by institutional investors while 28% of Aravive Inc. are owned by institutional investors. Insiders owned roughly 1.1% of Liquidia Technologies Inc.’s shares. On the other hand, insiders owned about 0.8% of Aravive Inc.’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Liquidia Technologies Inc. -0.1% -0.2% -31.03% -48.27% 0% -54.43%
Aravive Inc. 0% -0.16% 34.68% -8.68% -28.67% 82.39%

For the past year Liquidia Technologies Inc. has -54.43% weaker performance while Aravive Inc. has 82.39% stronger performance.


On 7 of the 10 factors Liquidia Technologies Inc. beats Aravive Inc.

Liquidia Technologies, Inc., a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of human therapeutics. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension. The company is also developing LIQ865, which completed Phase Ib clinical trials for the treatment of local post-operative pain. It has strategic collaboration agreements with GlaxoSmithKline plc and Aerie Pharmaecuticals, Inc. Liquidia Technologies, Inc. was incorporated in 2004 and is headquartered in Morrisville, North Carolina.

Aravive, Inc., a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. It is developing AVB-S6-500, a GAS6 binding protein and AXL decoy receptor, for the treatment of ovarian cancer, as well as for renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer and pancreatic cancer. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is based in Houston, Texas.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.